Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28699
Title: Impact of hydrogel and hyaluronic acid rectal spacer on rectal dosimetry and toxicity in low-dose-rate prostate brachytherapy: a multi-institutional analysis of patients' outcomes.
Austin Authors: Lin, Yuan-Hong;Loon, Wee;Tacey, Mark A ;Bolton, Damien M ;Tan, Alwin;Chan, Yee ;Cham, Chee Wee;Ho, Huong;Guerrieri, Mario;Foroudi, Farshad ;Joon, Daryl Lim;McMillan, Kevin;Koufogiannis, George;Manohar, Paul;Liu, Madalena;Pham, Trung;Chao, Michael 
Affiliation: Radiation Oncology..
Urology..
Genesis Cancer Care Victoria, Ringwood East, Australia..
The Bays Hospital, Mornington, Australia..
Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia..
Ringwood Private Hospital, Ringwood East, Australia..
Issue Date: Dec-2021
Date: 2021-12-30
Publication information: Journal of contemporary brachytherapy 2021; 13(6): 605-614
Abstract: To report on rectal dosimetry and toxicity outcomes in men with prostate cancer (PCa) treated with iodine-125 low-dose-rate brachytherapy (LDR-BT) with or without polyethylene glycol hydrogel (HS) or hyaluronic acid (HA) rectal spacer (RS) insertion. Seventy consecutive men treated with LDR-BT between December 2017 and July 2019 were included in this study, including twenty-eight (40%) men who had RS insertion according to the preference of referring urologist, compared to a group of forty-two men (60%) without RS. Descriptive statistics were used to compare RS safety, dosimetric effects on organs at risk (rectum and urethra), and gastrointestinal (GI) and genitourinary toxicities (GU) (assessed using the CTCAE v.4) between the two groups of patients. The median prostate-rectal separation with RS at mid prostate was 10 mm (IQR, 8-11.5 mm). The median follow-up was 23.5 months. There were no post-operative complications for RS insertion. There was significantly reduced rectal dosimetry in RS-group vs. non-RS group; the median RV100 was 0.0 cc (IQR, 0.0-0.0 cc) vs. 0.4 cc (IQR, 0.1-1.1 cc) (p < 0.001), respectively. The mean rectal D1cc and D2cc were 52.4% vs. 84.2% (p < 0.001) and 45.7% vs. 70.0% (p < 0.001) for RS and non-RS group, respectively. There were no statistically significant differences in the mean urethral D20, D5, and D1. There were significantly less grade 1 acute and late GI toxicities in RS-group when compared to non-RS group (0% vs. 24%, p = 0.004 for acute GI toxicity; 4% vs. 33%, p = 0.003 for late GI toxicity). There were no reported acute or late grade 2 or above GI toxicities. Insertion of RS in men treated with LDR-BT is safe and resulted in a significant reduction in rectal dosimetry. The reduction in rectal dosimetry with RS insertion translates into significantly reduced acute and late GI toxicities.
URI: https://ahro.austin.org.au/austinjspui/handle/1/28699
DOI: 10.5114/jcb.2021.112110
ORCID: 0000-0002-5145-6783
0000-0002-1947-9694
0000-0002-3497-3746
0000-0003-2948-8495
Journal: Journal of contemporary brachytherapy
PubMed URL: 35079245
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/35079245/
ISSN: 1689-832X
Type: Journal Article
Subjects: low-dose-rate brachytherapy
prostate cancer
rectal dosimetry
rectal spacer
rectal toxicity
Appears in Collections:Journal articles

Show full item record

Page view(s)

48
checked on Apr 19, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.